Gilead Sciences

Incorporated in 1987, Gilead Sciences has established its headquarters in Foster City, California, United States. The company has a diversified business portfolio with a strong focus on five key health categories: antiviral products, other infectious diseases, cardiovascular conditions, inflammation and respiratory diseases, as well as hematology and oncology. Some of the most important brands under Gilead's umbrella include Truvada, a cornerstone drug for the treatment of HIV and pre-exposure prophylaxis (PrEP). Harvoni and Sovaldi are leading medications in the company's hepatitis C segment. Recently, Veklury (better known as remdesivir) gained significant attention as an antiviral medication for COVID-19. Additionally, Biktarvy is another prominent Gilead drug used in the management of HIV. Gilead Sciences' products and services have a significant global footprint, with the company operating in numerous countries across continents. The United States stands as a key market, alongside Europe, Asia, South America, and Africa. The company's market presence varies by region, adapting to local disease prevalence, regulatory environments, and healthcare systems. Gilead's extensive reach demonstrates its role as a major player in both developed and developing markets worldwide. (Powered by AI)